Bind therapeutics inc
WebSep 19, 2013 · Bind Therapeutics Inc. (NASDAQ: BIND) plans to offer 4.7 million shares at $14-$16 per share in its IPO, according to its S-1 filing with the SEC. The company will be listed on the Nasdaq... WebBIND initiated voluntary Chapter 11 bankruptcy protection on May 1, 2016, and conducted a sale of assets, pursuant to Section 363 of the Bankruptcy Code, during an auction held on July 25 and 26, 2016. About BIND Therapeutics BIND Therapeutics is a biotechnology company developing novel targeted therapeutics, primarily for the treatment of cancer.
Bind therapeutics inc
Did you know?
WebNov 9, 2015 · BIND Therapeutics is a clinical-stage nanomedicine company developing a pipeline of Accurins™, its novel targeted therapeutics designed to increase the concentration and duration of therapeutic payloads at disease sites while reducing exposure to healthy tissue. WebDec 16, 2015 · BIND Therapeutics, Inc. (NASDAQ:BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called ACCURINS®, today
Web2 days ago · The details for the presentation are as follows: Title: Phase 1/2 study of HST-1011, an oral CBL-B inhibitor, alone and in combination with anti-PD-1 in patients with advanced solid tumors. Session Title: Phase I and First-in-Human Clinical Trials in Progress. Session Date and Time: Tue., Apr. 18, 1:30-5:00 PM ET. Location: Poster Section 46. WebBIND THERAPEUTICS, INC. is a Massachusetts Foreign Corporation filed on October 27, 2006. The company's File Number is listed as 000936468. The Registered Agent on file for this company is Shadi Aryanpour and is located at 490 Beacon St., Chestnut Hill, MA 02476. The company's principal address is 325 Vassar Street, Cambridge, MA 02139.
WebOn May 1, 2016, DNIB Unwind, Inc. (f/k/a BIND Therapeutics, Inc.) and DNIB Subsidiary Corporation (f/k/a BIND Biosciences Security Corporation) (collectively, the "Debtors") … WebMay 24, 2024 · Hello, I Really need some help. Posted about my SAB listing a few weeks ago about not showing up in search only when you entered the exact name. I pretty …
WebApr 5, 2024 · SEATTLE, April 05, 2024 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced data highlights from presentations of ...
WebBIND Therapeutics, Inc. share price - Stocktwits is the best way to find out what is happening right now around the BIND stock and other stock companies and markets. … on the way package athens gaWebBIND Therapeutics, Inc (Filer) CIK: 0001385228 (see all company filings) IRS No.: 000000000 State of Incorp.: DE Fiscal Year End: 1231 Type: 10-K Act: 34 File No.: … on the way outdoorsWebPossess a deep understanding of protein engineering, purification and characterization, as well as diverse collaborative and management … on the way plumbing tucsonWebOct 14, 2015 · CAMBRIDGE, Mass.--(BUSINESS WIRE)-- BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called AccurinsTM, today announced the appointment of Arthur Tzianabos, Ph.D., president and chief scientific officer of OvaScience, Inc., to the … onthewaynow incWebMay 9, 2024 · A high-level overview of BIND Therapeutics, Inc. (BIND) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. on the way planet proofWebJul 27, 2016 · As reported on July 25, Cambridge, Massachusetts-based Bind Therapeutics was selling off most of its assets as part of bankruptcy proceedings. Pfizer had been … on the way moversWebBIND Therapeutics reports exercise of option to develop and commercialise an Accurin drug by Pfizer Unlike sensor systems in which receptors can bind to a variety of … ios gods subway surfer hack no jailbreak